[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Università degli Studi di Brescia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100648078","vippstar-g1-digital-early-intervention-for-visual-impairment-100648078",false,"NCT07717671","VIPPSTAR-G1 Digital Early Intervention for Visual Impairment","VIPPSTAR-G1: A Multicenter Randomized Controlled Trial Evaluating a Caregiver-mediated Digital Intervention to Promote Visual Function and Neurodevelopment in Infants at Risk of\u002FWith Visual Impairment","VIPPSTAR-G1","Inclusion Criteria: Study Sample 1 - Infants at Risk of Visual Impairment\n\n* Gestational age ≤32 weeks OR full-term\u002Fnewborns\\>32 weeks of age with neonatal distress (Apgar ≤5 at 10 minutes)\n* NAVEG score ≥3\n* At least one neurological or neuroimaging abnormality:\n\n  * 3 abnormal signs at ATNAT neurological examination OR Abnormal cranial ultrasound findings OR Abnormal MRI findings\n\nExclusion Criteria: Study Sample 1 - Infants at Risk of Visual Impairment\n\n* Epileptic encephalopathy\n* Parents unable to understand local language\n\nInclusion Criteria: Study Sample 2 - Infants\u002FToddlers With Visual Impairment\n\n* Age ≤42 months\n* Diagnosis of peripheral or cerebral visual impairment\n* Moderate or severe visual impairment documented by standardized visual acuity testing Exclusion Criteria: Study Sample 2 - Infants\u002FToddlers With Visual Impairment\n* Age \\>42 months\n* Refractory epilepsy or epileptic encephalopathy\n* Participation in another interventional study within previous 12 months\n* Parents unable to understand local language","ALL","1 Day","42 Months",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Visual impairment in infancy is associated with significant risks for neurodevelopmental impairment. Early intervention based on enriched visual and multisensory experiences may promote neuroplasticity and improve developmental outcomes, but implementation of intensive interventions in routine clinical practice remains challenging. The VIPPSTAR-G1 study evaluates a caregiver-mediated digital intervention delivered through a dedicated platform designed to support visual and neurodevelopmental functions in infants at risk of or with visual impairment, within a framework that promotes and strengthens the parent-child\u002Fcaregiver-child relationship.\n\nThis multicenter, multinational, single-blind randomized controlled trial will enroll 102 newborns at risk of visual impairment and an additional exploratory pilot subgroup of 48 infants and toddlers with established visual impairment. Participants will be randomized to receive either the VIPPSTAR digital intervention plus standard care or standard care alone. Outcomes include visual acuity, smooth pursuit, additional neuro-ophthalmological functions, neurodevelopmental measures, adaptive functioning, language development, parental stress, quality of life, and feasibility of the digital intervention.",[28,29,30,31],"Visual Impairment","Cerebral Visual Impairment","Neurodevelopmental Disorders","Prematurity",[33,34,35,36],"visual impairment","early intervention","digital health","prematurity","NOT_YET_RECRUITING","2026-07-16",{"date":40,"type":41},"2026-07-21","ACTUAL",{"date":43,"type":22},"2026-07-01",{"date":45,"type":22},"2028-06-30",{"name":47,"class":48},"Università degli Studi di Brescia","OTHER",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100599813","photodynamic-therapy-with-topical-application-of-a-znii-phthalocyanine-rlp068cl-and-red-light-for-the-treatment-of-moderate-to-severe-acne-vulgaris-100599813","NCT07089368","Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068\u002FCl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris","PHOTAC","Inclusion Criteria:\n\n* Male or female participants aged ≥16 years.\n* Diagnosis of moderate-to-severe acne vulgaris (comedonal, papulopustular, or cystic), with facial lesions symmetrically distributed.\n* Washout period of at least 6 months from prior oral acne treatments.\n* Washout period of at least 2 months from prior topical acne treatments.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Use of systemic or topical photosensitizing medications.\n* Known photosensitivity disorders.\n* Pregnancy or breastfeeding.\n* Participation in another interventional clinical study within the past 3 months.\n* Any dermatological condition of the face that may interfere with treatment assessment (e.g., eczema, rosacea).\n* Any serious uncontrolled medical condition deemed by the investigator to pose a risk to the participant or interfere with study results.","16 Years",{"count":59,"type":22},10,[25],"This pilot clinical study will evaluate the safety, tolerability, and effectiveness of a novel photodynamic therapy (PDT) for moderate-to-severe acne vulgaris. PDT combines a topical photosensitizing gel with red light to treat acne lesions. The gel to be used in this study, called RLP068\u002FCl (a zinc phthalocyanine compound), has demonstrated antimicrobial, anti-inflammatory, and sebosuppressive effects in laboratory studies.\n\nA total of 10 patients with moderate-to-severe acne on the face will be enrolled. RLP068\u002FCl 0.3% gel will be applied topically for 30 minutes under occlusion, followed by 8 minutes of red LED light exposure. Treatments will be performed twice weekly, with the total number of sessions individualized based on clinical response.\n\nAcne severity will be assessed using the Global Acne Grading System (GAGS). Pain levels will be recorded after each session using a visual scale, and patient satisfaction will be evaluated at the end of the treatment cycle.\n\nThe goal of the study is to determine whether RLP068\u002FCl-PDT is a safe, well-tolerated, and effective non-antibiotic treatment option for patients with moderate-to-severe acne vulgaris who may not respond to or tolerate conventional therapies.",[63],"Acne","2026-04-28",{"date":66,"type":41},"2026-05-04",{"date":68,"type":22},"2026-08",{"date":70,"type":22},"2027-04",{"name":47,"class":48},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100617268","repetitive-transcranial-magnetic-stimulation-in-frontotemporal-lobar-degeneration-100617268","NCT07316413","Repetitive Transcranial Magnetic Stimulation in Frontotemporal Lobar Degeneration","FTLD_rTMS","Inclusion Criteria:\n\n* diagnosis of FTLD (bvFTD, avPPA, svPPA, CBS, or PSP)\n* global CDR plus NACC FTLD ≤ 1\n\nExclusion Criteria:\n\n* presence of cerebrovascular disease, hydrocephalus, intracranial masses identified by MRI, history of head trauma, serious medical conditions unrelated to FTLD, history of epilepsy, and presence of electronic (e.g., pacemaker) or metallic implants in the head.","18 Years",{"count":81,"type":22},120,[25],"The aim of the study is to evaluate the safety, feasibility, clinical and biological efficacy, and predictors of efficacy of an intervention consisting of repetitive transcranial magnetic stimulation (rTMS) in patients with frontotemporal dementia (FTLD) or in asymptomatic persons at risk of FTLD (i.e., persons familiar with FTLD patients).\n\nrTMS is a non-invasive brain stimulation technique, and has demonstrated the ability to modulate neuronal activity by applying high-frequency magnetic fields to the surface of the skull. rTMS offers a potentially effective means to influence neural networks involved in the pathogenesis of neurodegenerative diseases, with benefits that could extend beyond symptomatic relief. Its safety has been widely documented in a variety of clinical conditions, making it an ideal candidate for application in neurodegenerative diseases.\n\nIn the present study, participants will undergo the following procedures: (i) clinical and neuropsychological assessment, (ii) TMS, and (iii) blood sampling. The occurrence of adverse events will be monitored throughout the duration of the study.\n\nThe study is structured in two phases. In the first phase, double-blind, randomised and placebo-controlled, participants will be randomised into two groups: group 1, participants will receive real rTMS for 2 weeks; and group 2, placebo rTMS for 2 weeks. In the second, open-label phase, after 10 weeks, both group 1 and group 2 participants will receive real rTMS for 2 weeks. Each participant will receive a total of 4 weeks of intervention (4 weeks of real stimulation in group 1, or 2 weeks of real stimulation and 2 weeks of placebo stimulation in group 2), with 5 sessions per week (Monday to Friday) lasting approximately 30 minutes each.\n\nVisits will take place at the beginning of the study (T00) and after 2 weeks (T02, end of the first phase), 12 weeks (T12, beginning of the second phase), 14 weeks (T14, end of the second phase), 24 weeks (T24, follow-up). During each visit, participants underwent the following procedures: (i) clinical and neuropsychological assessment, (ii) blood sampling, and (iii) TMS. Specific biomarker analyses will be performed on the blood samples to study the pathophysiological mechanisms of the disease and the effect of the experimental intervention.",[85,86,87,88,89,90,91,92],"FTLD","FTD","bvFTD","PPA","PSP","Cortical Basal Syndrome (CBS)","rTMS","Theta Burst Stimulation","RECRUITING","2025-12-18",{"date":96,"type":41},"2026-01-05",{"date":98,"type":41},"2025-02-13",{"date":100,"type":22},"2029-02-01",{"name":47,"class":48},1,""]